Skip to main content
. 2026 Feb 9;18(4):560. doi: 10.3390/cancers18040560
PC Prostate cancer
mCRPC Metastatic castration-resistant prostate cancer
ADT Androgen deprivation therapy
ARSI Androgen receptor signaling inhibitor
PARPi PAR inhibitor
HRR Homologous recombination repair
PFS Progression-free survival
OS Overall survival
CDX Cell-derived xenograft 
PSA Prostate-specific antigen 
AR Androgen receptor
NEPC Neuroendocrine prostate cancer 
DDR DNA damage response